The aim of this post hoc pooled-data analysis was to evaluate the effects of once-daily tadalafil in men with mild or moderate ED and aged o50 or X50 years. Data from three randomized controlled trials were analyzed. Analysis of covariance models included a term for ED severity and age group. The three coprimary outcome measures in the base studies were changes from baseline to end point in the mean International Index of Erectile Function Erectile Function (IIEF-EF) domain score and the mean per-patient percentage successful vaginal penetration and intercourse attempts. Irrespective of baseline severity, once-daily tadalafil 5 mg for 12 weeks compared with placebo significantly increased the mean: (1) IIEF-EF by 6.8; (2) percent successful penetration attempts from 70.1 to 91.3%; and (3) percent successful intercourse attempts from 33.4 to 76.8% (each Po0.001). Treatment-by-age-group interaction P-values for all three coprimary efficacy end points exceeded 0.10, indicating that tadalafil treatment effects did not differ by age o50 vs X50 years. Tadalafil was generally well tolerated.
INTRODUCTION
Most cases of ED are mild or moderate. [1] [2] [3] Although the frequency and severity of ED increase with age, 1,2,4-8 men with mild/moderate ED also warrant medical attention but may not seek it.
1,2,5-9 Most men aged 450 years remain sexually active, yet many report sexual dissatisfaction. 10, 11 Age 50 can be viewed as an 'inflection point' for ED frequency. 2, [12] [13] [14] In registration trials involving phosphodiesterase type 5 (PDE5) inhibitors, the average patient age was 56-60. [15] [16] [17] There are pathophysiologic foundations for increases in ED severity and decreases in intercourse frequency after the age 50. 14, 18, 19 PDE5 inhibitors are first-line ED therapies. Tadalafil's long half-life renders the agent suitable for once-daily administration. 20 The approval of once-daily tadalafil signaled a paradigm shift in ED management. 21 In clinical trials, once-daily tadalafil improved erectile function and sexual satisfaction (vs placebo). [22] [23] [24] [25] [26] [27] [28] However, none of these studies evaluated the efficacy and safety profiles of once-daily tadalafil specifically in men with mild (vs moderate) ED or aged X50 (vs o50) years. The objective of the present analysis was to evaluate the efficacy and safety of once-daily tadalafil 2.5 or 5 mg (vs placebo) in men with mild or moderate ED and aged o50 or X50 years. We hypothesized that tadalafil would have similar effects across the two subgroups of ED severity and the two other subgroups of patient age.
PATIENTS AND METHODS

Designs of the base studies
This post hoc pooled-data analysis included men from three 'base' internal studies: Study H6D-MC-LVCV; 27 Study H6D-MC-LVFP (NCT00381732); 28 and Study identifier H6D-MC-LVGH (ClinicalTrials.gov identifier NCT00422734). 22, 23 Study LVCV was conducted in South America, Germany and the United Kingdom (no ClinicalTrials.gov identifier); Study LVFP was conducted in the United States; and Study LVGH was conducted in Europe, Mexico and the United States. Similarities of all three base studies included the fact that they were multicenter, randomized, doubleblind, parallel-group and placebo-controlled trials. Each base study was also composed of a 4-week treatment-free run-in and at least a 12-week double-blind treatment interval. All studies conformed to the Declaration of Helsinki. Differences included the fact that Study LVFP also included a 24-week double-blind treatment period, although only 12-week data are reported herein. Only Study LVCV evaluated the effects of once-daily tadalafil 10 mg. However, data on this dose were not incorporated in the present analysis because only the lower two tadalafil doses (that is, 2.5 and 5 mg) have been approved for daily dosing by regulatory agencies. 29 
Subjects in the base studies
Men with ED of all severities who were in stable heterosexual relationships were eligible for the base studies if they agreed to make X4 intercourse attempts during a 4-week treatment-free run-in and met other eligibility criteria (Appendix).
Procedures
Conducted sequentially, each base study was composed of the run-in and a 12-to 24-week double-blind treatment interval. Eligible patients were randomized, with stratification by ED severity and geographic region, to once-daily: (1) tadalafil 5 mg (n ¼ 109), 10 mg (n ¼ 105; data on dose not included herein), or placebo (n ¼ 54; N ¼ 268) in Study LVCV; (2) 2.5 mg (n ¼ 96), 5 mg (n ¼ 97), or placebo (n ¼ 94; N ¼ 287) in Study LVFP; and (3) 5 mg (n ¼ 264) or placebo (n ¼ 78; N ¼ 342) in Study LVGH.
ED severity was classified according to the International Index of Erectile Function Erectile Function domain (IIEF-EF); 30, 31 for randomization, the mild and mild-to-moderate categories were combined. Hence, subjects were stratified based on ED severity of mild (IIEF-EF ¼ 17-30), moderate (IIEF-EF ¼ 11-16) or severe (IIEF-EF ¼ 1-10) ED. Our a priori data analysis plan called for us to be statistically parsimonious by pooling data from the three base randomized controlled trials involving tadalafil while conserving the basic statistical analytical methods of each of these base randomized controlled trials in terms of baseline ED severity categories, outcome measures, analysis-of-covariance (ANCOVA) models and other salient details. To be consistent with these previously conducted tadalafil studies, we combined the 'mild' and 'mild-to-moderate' IIEF-EF categories into a single 'mild' category for the purposes of randomization to study medication. However, there was no upper limit of IIEF-EF domain score at the end of the non-drug lead-in periods that was exclusionary. In the base studies, IIEF-EF scores for the mild category ranged from 17 to 30, and some subjects had baseline IIEF-EF domain scores indicative of 'no ED' (X26). 30, 31 Assessments and outcome measures in the base studies 
Statistical analysis
The three base studies were powered to detect differences in the three coprimary end points (IIEF-EF, SEP2, SEP3), using a two-sided a ¼ 0.05 but were not designed to detect differences within patient subgroups (mild vs moderate ED or age o50 vs X50 years).
Our analysis population included all subjects with baseline IIEF-EF 410 who were randomized to placebo, 2.5 or 5 mg and had data at baseline and X1 post-baseline visit. Missing data were imputed by LOCF. Efficacy analyses were based on 12-week data.
Baseline demographic parameters were summarized using descriptive statistics. Changes from baseline in efficacy parameters were assessed using ANCOVA models including terms for protocol, centered-baseline, treatment group and centered-baseline-by-treatment interaction.
Two subgroup efficacy analyses were conducted using ANCOVA to compare treatment effects with once-daily tadalafil (vs placebo) in subjects aged o50 vs X50 and mild vs moderate ED. For each subgroup analysis, ANCOVA models also included terms for protocol, centered-baseline, treatment group and centered-baseline-by-treatment interaction, as well as subgroup variables (age or ED severity) and subgroup-by-treatment interactions. Within-subgroup least squares means for treatment differences (and associated P-values) were reported if the treatment-by-subgroup interaction P-value was o0.100. Because P-values for the treatment-by-age-subgroup interactions analyses in fact exceeded 0.100 for IIEF and SEP efficacy end points, the age term was removed from the corresponding ANCOVA models; least squares means and P-values were available and are reported for the overall treatment effects only (but not within-age-subgroup effects). Hence, only descriptive statistics are reported for within-age-group treatment comparisons.
Proportions of subjects with baseline IIEF-EF o26 who experienced normalization 31 at end point were summarized overall and by subgroup, and analyzed using a w 2 test. Safety analyses included all subjects in the analysis population previously described. Data on treatment-emergent adverse events (TEAEs) occurring in X2% of subjects in any group, or with higher frequency in the tadalafil groups, were presented. TEAEs were organized and presented using Medical Dictionary for Regulatory Affairs Version 13.1 preferred terms.
RESULTS
Numbers (%) of subjects included in the base studies and current analysis population In the three base trials, 897 subjects were randomized. 23, 27, 28 Among them, 148 subjects in the placebo group, 57 in the 2.5-mg group and 317 in the 5-mg group (N ¼ 522; 58.2%) had mild or moderate ED and evaluable efficacy data at baseline and end point or LOCF, and hence comprised the present analysis population.
Baseline characteristics Treatment groups were well balanced (Table 1) . Subjects with mild ED had higher IIEF-EF domain scores (mean IIEF-EF ¼ 21.0 vs 13.4) and were slightly younger (mean age ¼ 54.6 vs 56.0 years) than those with moderate ED.
When stratified by age, men o50 years were B18 years younger than those X50 (mean age ¼ 42.8 vs 60.9 years) but had similar EF domain scores (mean ¼ 18.2 vs 17.8, respectively). Men o50 also had a higher percentage of mild ED (66.5% vs 56.3%), a lower percentage of mixed/organic etiology (70.7% vs 87.6%) and a lower frequency of hypertension (16.2% vs 38.9%) or diabetes (9.0% vs 16.9%).
Efficacy
In the overall study population, tadalafil significantly improved perpatient 'yes' responses to SEP2 and SEP3 (Table 2 ; Figures 1 and 2 ), as well as mean scores on the IIEF-EF domain ( Figure 3 ; Table 3 ) and also the IIEF Intercourse Satisfaction (IIEF-IS), IIEF Overall Satisfaction (IIEF-OS) and IIEF Sexual Desire (IIEF-SD) domains (Table 3) , compared with placebo (Po0.020 for each comparison).
ED severity subgroup analyses
Successful penetration (SEP2). The effect of tadalafil on successful penetration attempts differed significantly by ED severity (treatment-by-ED-severity interaction, P ¼ 0.001).
Treatment with once-daily tadalafil 2.5 or 5 mg significantly increased per-patient 'yes' responses to SEP2 from baseline in all subjects (Po0.001 vs placebo; Figure 1 and Table 2 ). In subjects with mild ED, once-daily treatment with 5 mg significantly increased the successful penetration rate (P ¼ 0.015 vs placebo). In those with moderate ED, each tadalafil dose significantly increased penetration rates (Po0.001 vs placebo for each). Men with mild ED tended to have higher per-patient percentages of affirmative responses to SEP2 at both baseline and end point compared with those with moderate ED. However, men with moderate ED experienced overall greater improvements in SEP2 from baseline to end point. Mean per-patient percentages of successful penetration attempts after 12 weeks of treatment with 5 mg were 93.4% for men with mild ED and 88.2% for those with moderate ED (Figure 1 ).
Intercourse success (SEP3). The effect of tadalafil treatment on completion of successful intercourse also differed significantly by ED severity (treatment-by-ED-severity interaction, P ¼ 0.049).
The per-patient 'yes' responses to SEP3, or the ability to successfully complete intercourse, increased significantly with both tadalafil doses (Po0.001 vs placebo; Table 2 and Figure 2 ). Subjects with mild ED experienced a significant increase in successful intercourse rates when treated with either 2.5 mg (P ¼ 0.013 vs placebo) or 5 mg (Po0.001 vs placebo). In those with moderate ED, both tadalafil doses significantly increased successful intercourse rates (Po0.001 vs placebo).
Study participants with mild ED tended to have higher baseline and end point per-patient percentages of 'yes' responses to SEP3, whereas those with moderate ED had a lower percentage for each but had numerically greater increases from baseline to end point ( Figure 2 ). The mean per-patient percentages of successful intercourse attempts after 12 weeks of treatment with 5 mg were 81.5% for men with mild ED and 69.8% for those with moderate ED.
IIEF domains. EF domain: the effect of tadalafil significantly differed by baseline ED severity (treatment-by-ED-severity interaction, Po0.001).
Treatment with the 2.5-mg dose significantly increased the mean IIEF-EF domain score from baseline to end point compared with placebo in men with mild ED (P ¼ 0.032; Figure 3 ).
The mean baseline and end point IIEF-EF domain scores tended to be higher in study participants with mild ED (and lower in those with moderate ED). However, men with moderate ED experienced greater numerical improvements from baseline on active treatment compared with those with mild ED (Figure 3 ). The mean end point value for the IIEF-EF domain in subjects with mild ED at In addition to the improvement in the mean IIEF-EF domain score, there were numerical (P40.05) differences in normalization of erectile function (end point IIEF-EF X26) by baseline ED severity. Among subjects with mild ED and baseline IIEF-EF o26, the mean percentage of men with normalization of erectile function at end point was 28.8% with placebo, 58.6% with 2.5 mg and 67.3% with 5 mg. In those with moderate ED and baseline IIEF-EF o26, normalization at end point occurred in 3.4% (placebo), 40.9% (2.5 mg) and 53.6% (5 mg) of subjects.
Other IIEF domains. Treatment-by-ED-severity interactions were not significant for other IIEF domains. However, there were numerical improvements in favor of tadalafil. Mean increases in the IIEF-IS domain score from baseline to end point in subjects with mild ED were 0.7 with placebo, 2.2 with 2.5 mg and 2.3 with 5 mg. Respective mean increases in men with moderate ED within these treatment groups were 0.3, 3.1, and 3.4.
Once-daily treatment increased IIEF-OS domain scores from baseline to end point in subjects with mild ED by a mean value of 0.7 with placebo, 1.7 with 2.5 mg, and 2.1 with 5 mg. Respective increases in subjects with moderate ED were 0.7, 2.9, and 3.1.
The IIEF-SD domain score was unchanged from baseline to end point with once-daily placebo in subjects with mild ED, compared with mean increases of 0.3 with 2.5 mg and 0.7 with 5 mg. In those with moderate ED, the IIEF-SD domain score decreased by a mean of 0.2 with placebo and increased by mean values of 1.0 with 2.5 mg and 0.7 with 5 mg.
Age subgroup analyses
The treatment-by-age-group interaction was not significant for the IIEF-EF domain and the SEP questions. However, there were numerical improvements for successful penetration, successful The line within each bar, and the number immediately below it, represent the baseline mean value. The number at the bottom of each bar represents the mean change from baseline to end point. Some differences between mean end point and baseline values do not equal the mean change value because of rounding. *Po0.001; w P ¼ 0.015 for comparisons vs placebo. N ¼ number of subjects. (b) As the P-value for the treatment-by-age-subgroup interactions analyses exceeded 0.10 for SEP2 (P ¼ 0.281), the age term was removed from the final analysis-of-covariance models; least squares means and P-values were available and are reported for the overall treatment effects only (but not for within-age-subgroup effects). As the P-value for the treatment-by-age-subgroup interactions analyses exceeded 0.10 for SEP3 (P ¼ 0.244), the age term was removed from the final analysis-of-covariance models; least squares means and P-values were available and are reported for the overall treatment effects only (but not for within-age-subgroup effects).
intercourse completion and the IIEF-EF domain in favor of tadalafil over placebo within each age group (Figures 1b, 2b, and 3b ).
Successful penetration (SEP2). Treatment with once-daily tadalafil 2.5 or 5 mg increased per-patient 'yes' responses to SEP2 from baseline (Po0.001 vs placebo; Figure 1b and Table 2 ). In general, mean baseline and end point values for SEP2 were higher in men o50 years than their older counterparts. Although older men also experienced increases in successful penetration rates with each dose of tadalafil, the improvement was larger (vs younger subjects) only in older men receiving 5 mg (Figure 1b) . The mean per-patient percentages of successful penetration at end point with 5 mg were 94.2% for men o50 and 89.9% for those X50 years of age.
Intercourse success (SEP3). Similar patterns of improvement were observed in the per-patient percentage of ' yes' responses to SEP3.
Men aged o50 years tended to have higher baseline and end point SEP3 values, as well as greater improvements in SEP3 from baseline, compared with those X50 (Figure 2b ). Mean per-patient percentages of successful intercourse attempts at end point with 5 mg were 84.4% in subjects aged o50 years and 73.1% in their older counterparts.
IIEF domains. Treatment-by-age-group interactions for the IIEF-EF, IS, OS and SD domains were also not significant. Hence, no Pvalues for comparisons between active treatment and placebo are reported within age groups.
Men aged o50 experienced higher values for the IIEF-EF domain at baseline and end point, as well as greater increases from baseline, as compared with their older counterparts (Figure 3b ). Younger men receiving 2.5 or 5 mg had mean end point IIEF-EF scores (425) that approached or exceeded the threshold associated with no ED (IIEF-EF X26). 31 In older men, mean increases in the IIEF-EF domain were 0.3 with placebo, 5.2 with 2.5 mg and 6.4 with 5 mg.
Normalization of erectile function 31 at end point among subjects with baseline IIEF-EF o26 also did not differ significantly by age. Normalization of erectile function occurred in a mean of 14.6% of subjects aged o50 receiving placebo, 75.0% of those receiving 2.5 mg and 68.8% of those receiving 5 mg. Respective mean values in men X50 were 18.7% (placebo), 40.0% (2.5 mg) and 57.7% (5 mg).
In subjects aged o50 years, the IIEF-IS domain score increased from baseline to end point by a mean of 0.7 with placebo, 3.1 with 2.5 mg and 3.2 with 5 mg. In older subjects, respective mean increases were 0.5, 2.3 and 2.6.
The IIEF-OS score increased from baseline to end point by a mean of 0.7 with placebo, 2.6 with 2.5 mg and 2.9 with 5 mg in subjects aged o50 years. Respective data in those X50 were mean increases of 0.7, 2.0 and 2.3.
Study participants aged o50 years experienced mean increases from baseline to end point in the IIEF-SD domain score of 0.1 with placebo, 0.4 with 2.5 mg and 0.7 with 5 mg. Their counterparts aged X50 experienced a mean decrease of 0.2 with placebo and an increase of 0.7 with each dose of tadalafil. Safety Once-daily tadalafil was generally well tolerated. TEAEs occurring in 43% of subjects within any treatment group included headache, dyspepsia, nasopharyngitis, back pain and myalgia (Table 4) . Overall frequencies of TEAEs were similar across baseline ED severity and age categories.
DISCUSSION
In the present post hoc pooled-data analysis of three randomized, double-blind, placebo-controlled studies, men with mild or moderate ED experienced significant improvements in erectile function across all end points with once-daily tadalafil 5 mg (vs placebo). Irrespective of baseline ED severity, tadalafil 5 mg once daily significantly increased mean per-patient percentages of (1) successful penetration and (2) successful intercourse. Treatment with tadalafil was also generally well tolerated, with both the range of observed TEAEs and their incidences being similar to data from previous trials of PDE5 inhibitors. 15, 32, 33 Mean placebo-adjusted increases in IIEF-EF exceeded ED severity-specific thresholds associated with (the recently published) minimum clinically important differences (MCIDs; improvements) in the IIEF-EF domain 34 in each group of men who received 5 mg, including 4.1 in subjects with mild ED (threshold MCID ¼ 2) and 9.4 in those with moderate ED (threshold MCID ¼ 5). Corresponding values in men aged o50 and X50 years, respectively, were 6.5 and 6.1. As the P-value for the treatment-by-age subgroup interactions analyses exceeded 0.10 for the IIEF-EF domain (P ¼ 0.397), the age term was removed from the final analysis-of-covariance models; least squares means and P-values were available and are reported for the overall treatment effects only (but not for within-age-subgroup effects).
Regarding our hypotheses, baseline-to-end point improvements in erectile function with 5 mg (vs placebo) were numerically greater in men with moderate (vs mild) ED, although men with mild ED experienced higher end point values, across both SEP diary questions and the IIEF-EF domain. Similarly, compared with their counterparts aged X50 years, younger men experienced numerically greater increases from baseline in responses to SEP2, SEP3 and the IIEF-EF domain after once-daily tadalafil treatment. However, because the treatment-by-age-subgroup interaction was not significant, effects of treatment (vs placebo) on these parameters could not be compared across patient age groups. Men o50 years of age had a similar mean baseline IIEF-EF domain score despite being, on average, B18 years younger than subjects X50 years and also having lower frequencies of organic ED and of vascular comorbidities. Participants in our three base studies who had mild ED at baseline and received 5 mg for 12 weeks experienced successful penetration in B93% of attempts, and successfully completed intercourse in B82% of attempts. Approximately 69-75% of men aged o50 years at baseline experienced normal erectile function after 12 weeks of treatment with 2.5 or 5 mg (vs 15% with placebo). The mean IIEF-EF domain score at study end point in each of these active-treatment groups among men o50 (26.1 and 25.4, respectively) exceeded or approached the threshold for no ED (IIEF-EF ¼ 26). 31 Potential limitations These analyses were designed to address prescribers' questions regarding the use of tadalafil once daily in subgroups based on patient age and disease severity. However, providing this information is not without limitations. The chief limitation of our post hoc analysis is that the base studies were not designed or powered to evaluate within-subgroup (that is, by baseline ED severity or age) treatment differences. Most data were contributed by men aged X50 (and with mild ED), and the 2.5-mg arm was small (n ¼ 57). The 2.5-mg treatment arm was small because only Study LVFP 28 evaluated the effects of 2.5 mg once daily. Compared with study participants receiving tadalafil 5 mg in the other two studies, men in the 2.5-mg group were 3-5 years older and had a higher proportion of subjects with vascular comorbidities. The inclusion of a small number of subjects who were treated with a different dose of tadalafil may have introduced a certain degree of heterogeneity and the possibility of Type II (b) error. Data from our 2.5-mg group may not be as generalizable to larger patient populations. Further, our statistical analyses were not corrected for multiple comparisons, and the findings may not be generalizable to a larger population of men with severe ED. Post hoc analyses establish associations rather than causality. The base studies, which excluded men with a history of poor responses to PDE5 inhibitors, 23, 27, 28 and the current analyses of men with mild or moderate ED, may have biased our study sample toward overall less severe disease. Consequently, our analysis population may have been subject to a 'ceiling effect. ' Consistent with previously conducted tadalafil ED studies, the mild and mild-to-moderate ED severity categories were combined for the purposes of randomization to study medication. In addition, there was no upper limit of IIEF-EF domain score after the treatment-free lead-in periods that was exclusionary. Hence, IIEF-EF scores for the mild category ranged from 17 to 30. This resulted in the inclusion of 24 men with IIEF-EF scores consistent with no ED (X26). 31 This criterion may also have contributed to an overall more mild rather than moderate ED population and biased our findings toward higher baseline erectile function. However, a sensitivity analysis that excluded data from these subjects (men with no ED at baseline) revealed similar findings in terms of treatment effect sizes, directions and P-values.
With regard to age, one limitation is that efficacy findings were assessed across age categories rather than as a function of advancing age as a continuous variable. There are potential statistical pitfalls associated with dichotomizing a continuous variable (age), as our analysis did. Previous studies have focused on comparisons of tadalafil efficacy in men older or younger than 65 years, but not older or younger than 50 specifically. 35, 36 Although there are pathobiological reasons to speculate that men aged X50 would experience reduced sexual function, this age cut point in our analysis was somewhat arbitrary (apart from the reported interest of prescribers in responses to tadalafil in patients aged X50 or o50 years of age).
Conclusions
Men with mild or moderate ED experienced significant improvements in erectile function with once-daily tadalafil. Tadalafil was generally well tolerated. As indicated by the failure to detect a statistically significant treatment-by-age-group interaction, efficacy profiles overall were similar in men aged o50 or X50 years.
